MX2017008994A - Formulacion de peptidos inhibidores mk2. - Google Patents
Formulacion de peptidos inhibidores mk2.Info
- Publication number
- MX2017008994A MX2017008994A MX2017008994A MX2017008994A MX2017008994A MX 2017008994 A MX2017008994 A MX 2017008994A MX 2017008994 A MX2017008994 A MX 2017008994A MX 2017008994 A MX2017008994 A MX 2017008994A MX 2017008994 A MX2017008994 A MX 2017008994A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- described invention
- inhibitor peptides
- pharmaceutical formulation
- provides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229940124789 MK2 inhibitor Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101190P | 2015-01-08 | 2015-01-08 | |
| PCT/US2016/012650 WO2016112292A1 (en) | 2015-01-08 | 2016-01-08 | Formulation of mk2 inhibitor peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008994A true MX2017008994A (es) | 2018-09-18 |
Family
ID=56356475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008994A MX2017008994A (es) | 2015-01-08 | 2016-01-08 | Formulacion de peptidos inhibidores mk2. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10087225B2 (enExample) |
| EP (1) | EP3242886A4 (enExample) |
| JP (1) | JP2018502860A (enExample) |
| KR (1) | KR20170102900A (enExample) |
| CN (1) | CN107406489A (enExample) |
| AU (1) | AU2016205125A1 (enExample) |
| BR (1) | BR112017014737A2 (enExample) |
| CA (1) | CA2972916A1 (enExample) |
| HK (1) | HK1246807A1 (enExample) |
| MX (1) | MX2017008994A (enExample) |
| RU (1) | RU2017128077A (enExample) |
| SG (1) | SG11201705559RA (enExample) |
| WO (1) | WO2016112292A1 (enExample) |
| ZA (1) | ZA201704495B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201902326XA (en) | 2014-09-17 | 2019-04-29 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
| JP7216073B2 (ja) | 2018-03-13 | 2023-01-31 | 株式会社Adeka | 非水電解質二次電池 |
| US20210322310A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable Formulation of a Solution Containing Tiotropium Bromide |
| CN111647088B (zh) * | 2020-06-29 | 2023-05-02 | 东北师范大学 | 细胞渗透短肽tat-hns-3及对炎性疾病的应用 |
| AU2023207395A1 (en) | 2022-01-14 | 2024-07-11 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AT396872B (de) | 1985-07-30 | 1993-12-27 | Glaxo Group Ltd | Gerät zur verabreichung von medikamenten in pulverform |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| HUE026826T2 (en) * | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| EP2617431B1 (en) | 2007-01-10 | 2017-04-12 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| DK2349310T3 (da) * | 2008-10-20 | 2014-08-11 | Moerae Matrix Inc | Polypeptid til behandling eller forebyggelse af adhæsioner |
| BRPI0922448A2 (pt) | 2008-12-10 | 2021-02-17 | Purdue Research Foundation | inibidor com base em peptídeo penetrante celular de quinases |
| WO2011017132A2 (en) | 2009-07-27 | 2011-02-10 | Purdue Research, Foundation | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20110288036A1 (en) | 2010-05-24 | 2011-11-24 | Cynthia Lander | Methods for Treating or Preventing Vascular Graft Failure |
| ES2711670T3 (es) | 2011-04-12 | 2019-05-06 | Moerae Matrix Inc | Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US20140072613A1 (en) | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
| US9102015B2 (en) * | 2013-03-14 | 2015-08-11 | Siemens Energy, Inc | Method and apparatus for fabrication and repair of thermal barriers |
| CN105431134A (zh) * | 2013-04-11 | 2016-03-23 | 范德比尔特大学 | 复合物 |
-
2016
- 2016-01-08 MX MX2017008994A patent/MX2017008994A/es unknown
- 2016-01-08 HK HK18106201.2A patent/HK1246807A1/zh unknown
- 2016-01-08 SG SG11201705559RA patent/SG11201705559RA/en unknown
- 2016-01-08 CA CA2972916A patent/CA2972916A1/en not_active Abandoned
- 2016-01-08 KR KR1020177021042A patent/KR20170102900A/ko not_active Withdrawn
- 2016-01-08 BR BR112017014737A patent/BR112017014737A2/pt not_active Application Discontinuation
- 2016-01-08 RU RU2017128077A patent/RU2017128077A/ru not_active Application Discontinuation
- 2016-01-08 WO PCT/US2016/012650 patent/WO2016112292A1/en not_active Ceased
- 2016-01-08 EP EP16735478.6A patent/EP3242886A4/en not_active Withdrawn
- 2016-01-08 CN CN201680005237.6A patent/CN107406489A/zh active Pending
- 2016-01-08 AU AU2016205125A patent/AU2016205125A1/en not_active Abandoned
- 2016-01-08 JP JP2017536526A patent/JP2018502860A/ja active Pending
- 2016-01-08 US US14/991,531 patent/US10087225B2/en not_active Expired - Fee Related
-
2017
- 2017-07-03 ZA ZA2017/04495A patent/ZA201704495B/en unknown
-
2018
- 2018-08-21 US US16/106,504 patent/US20190031730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017128077A3 (enExample) | 2019-09-30 |
| CA2972916A1 (en) | 2016-07-14 |
| AU2016205125A2 (en) | 2017-10-19 |
| SG11201705559RA (en) | 2017-08-30 |
| CN107406489A (zh) | 2017-11-28 |
| KR20170102900A (ko) | 2017-09-12 |
| ZA201704495B (en) | 2019-01-30 |
| US10087225B2 (en) | 2018-10-02 |
| EP3242886A4 (en) | 2018-08-29 |
| JP2018502860A (ja) | 2018-02-01 |
| EP3242886A1 (en) | 2017-11-15 |
| US20160200782A1 (en) | 2016-07-14 |
| BR112017014737A2 (pt) | 2018-01-16 |
| AU2016205125A1 (en) | 2017-07-13 |
| US20190031730A1 (en) | 2019-01-31 |
| RU2017128077A (ru) | 2019-02-08 |
| WO2016112292A1 (en) | 2016-07-14 |
| HK1246807A1 (zh) | 2018-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017008994A (es) | Formulacion de peptidos inhibidores mk2. | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| MX2023001877A (es) | Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| PH12017550134A1 (en) | Il-37 variants | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| EP2552462A4 (en) | CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| PH12018500468A1 (en) | Fusion protein | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
| EP3925968A3 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
| MY204884A (en) | Peptide for treating age-related macular degeneration | |
| MX392412B (es) | Polipéptidos que tienen actividad inductora de inmunidad. | |
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. |